Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Official title

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Study identification

NCT ID

NCT03150693

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Alliance for Clinical Trials in Oncology

Other

Enrollment

310 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 39 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 19, 2017

Primary completion

Feb 28, 2027

Completion

Jul 31, 2027

Last update posted

May 7, 2026

2017 – 2027

United States locations

U.S. sites

455

U.S. states

40

U.S. cities

282

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.